Caspian Therapeutics
Caspian Therapeutics is a biopharmaceutical brand name for which no verifiable public brand information was supplied.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Caspian Therapeutics is presented here as a biopharmaceutical brand name, but the supplied evidence contains no information about this entity. The only source provided is a news article about the opening of a replacement passenger terminal at Hollywood Burbank Airport, which has no connection to a company called Caspian Therapeutics. No official website, founding record, headquarters location, ownership structure, product pipeline, executive team, or market activity could be confirmed from the available material. Because the name follows a common convention for biotechnology and pharmaceutical companies (a geographic or evocative word paired with "Therapeutics"), it is plausible that Caspian Therapeutics is a drug-development venture, but this cannot be verified and should not be asserted. No products, clinical programs, partnerships, funding events, or regulatory milestones are documented in the evidence. This entry is therefore a placeholder pending reliable sources. It should not be treated as a confirmed commercial brand profile, and any downstream use should await verification of the company's existence, legal identity, and offerings through official filings, a corporate website, or reputable business press.
Recent events
- Unconfirmed
Caspian Therapeutics raises $50 million in financing led by BVF Partners[2]
Reported:
Caspian Therapeutics has raised $50 million in financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura and other investors. The proceeds are expected to fund IND-enabling work, an initial clinical proof-of-concept program and advancement of a second menin inhibitor candidate.
- Unconfirmed
Kura Oncology forms Caspian Therapeutics to develop KO-7246 for diabetes[2]
Reported:
Kura Oncology has formed a new affiliate, Caspian Therapeutics, and contributed the oral menin inhibitor KO-7246, related intellectual property and know-how to it. Caspian will lead development of the diabetes program, while Kura retains approximately 50% ownership of Caspian and remains focused on oncology.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/caspian-therapeutics · Editorial policy · How profiles are compiled